Press Releases

SEATTLE --(BUSINESS WIRE)--Jun. 27, 2025-- Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic

SEATTLE --(BUSINESS WIRE)--Jun. 24, 2025-- Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 27, 2025 , starting at 10:00 a.m. Pacific Time .

– Conference Call Today at 4:30 p.m. ET SEATTLE --(BUSINESS WIRE)--May 15, 2025-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2025 , which include: Net loss for the first quarter of 2025 was

SEATTLE --(BUSINESS WIRE)--May 12, 2025-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended March 31, 2025 , on Thursday, May 15, 2025 , after the market closes. Omeros management will host a conference call and webcast that

SEATTLE --(BUSINESS WIRE)--May 12, 2025-- Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) today announced that it has entered into exchange agreements (the “Exchange Agreements”) with a limited number of investors who are holders of the Company’s 5.25% Convertible Senior Notes due

SEATTLE --(BUSINESS WIRE)--May 6, 2025-- Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell

– The Steering Committee brings together distinguished clinical experts in AML from leading National Comprehensive Cancer Network Centers – SEATTLE --(BUSINESS WIRE)--Apr. 10, 2025-- Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering

-- Targeted Complement Activating Therapy ™ Represents Next-Generation , Broadly Applicable Antimicrobial Therapeutics – SEATTLE --(BUSINESS WIRE)--Apr. 8, 2025-- Omeros Corporation (Nasdaq: OMER) today announced that the first public presentation of its proprietary Targeted Complement Activating

– Conference Call Today at 4:30 p.m. ET – SEATTLE --(BUSINESS WIRE)--Mar. 31, 2025-- Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2024 , which include: Net loss for the fourth

SEATTLE --(BUSINESS WIRE)--Mar. 26, 2025-- Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2024 , on Monday, March 31, 2025 , after the market closes. Omeros management will host a conference call and

-- Phase 3 Data Needed for BLA Submission Expected in the Fourth Quarter 2026 -- SEATTLE --(BUSINESS WIRE)--Mar. 21, 2025-- Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in

– Successful Completion of Animal Drug Interaction Studies Triggers Funding for Phase 1b Clinical Trial in Patients with CUD – SEATTLE --(BUSINESS WIRE)--Mar. 13, 2025-- Omeros Corporation (Nasdaq: OMER) today announced that it has received a funding commitment from the National Institute on Drug

– Results Demonstrate Marked Survival Superiority of Narsoplimab-Treated EAP Patients, in Stand-Alone and Combined Analyses with Narsoplimab Pivotal Trial Patients, over External Control Patients – Results of statistical analyses of survival in narsoplimab-treated expanded access program (EAP)

SEATTLE --(BUSINESS WIRE)--Feb. 14, 2025-- Omeros Corporation (Nasdaq: OMER) today announced the availability on its website of materials accompanying two presentations given at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation

SEATTLE --(BUSINESS WIRE)--Feb. 10, 2025-- Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy and the Center for

  – Newly Completed Sensitivity Analyses Demonstrate Robustness of Previously Announced Survival Superiority Over External Control in Patients with TA-TMA – Sensitivity analyses support the results of the primary endpoint analysis, with representative sensitivity analyses demonstrating: